Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07486934 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
A Phase 3 study, sponsored by Dyne Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT07486934 is a Phase 3 study that is actively recruiting participants, run by Dyne Therapeutics. The registered enrollment target is 150 participants.
The verdict
NCT07486934, a Phase 3 study, is actively recruiting participants, sponsored by Dyne Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment basivarsen (DYNE-101) for the treatment of myotonic dystrophy 1 (DM1).
Interventions
- DRUG Placebo
- DRUG zeleciment basivarsen (DYNE-101)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-05-14 |
| Est. Completion | 2029-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07486934
The ClinicalTrials.gov registry entry for NCT07486934 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dyne Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07486934 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07486934 about?
NCT07486934 is a clinical study titled "Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1". The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment basivarsen (DYNE-101) for the treatment of myotonic dystrophy 1 (DM1).
What is the current status of trial NCT07486934?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2026-05-14. Estimated completion is 2029-01.
What interventions are being tested in trial NCT07486934?
The interventions under investigation include: Placebo (DRUG), zeleciment basivarsen (DYNE-101) (DRUG).
Who is sponsoring clinical trial NCT07486934?
This trial is sponsored by Dyne Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.